Zydelig for Follicular Lymphoma – Details


( Last Updated : October 17, 2016)
Generic Name:
Idelalisib
Project Status:
Complete
Therapeutic Area:
Follicular Lymphoma
Manufacturer:
Gilead Sciences, Inc.
Brand Name:
Zydelig
Project Line:
Reimbursement Review
Project Number:
PC0075-000
NOC Date:

Details


Strength:
100mg & 150mg Tablets
Tumour Type:
Lymphoma
Indications:
Follicular Lymphoma
Funding Request:
For the treatment of patients with follicular lymphoma who have received at least two prior systemic therapies and are refractory to both rituximab and an alkylating agent
Review Status:
Complete
Sponsor:
Gilead Sciences, Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
Funding Request:
For the treatment of patients with follicular lymphoma who have received at least two prior systemic therapies and are refractory to both rituximab and an alkylating agent
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.